The latest price target for Benitec Biopharma (NASDAQ:BNTC) was reported by Guggenheim on September 12, 2024. The analyst firm set a price target for $17.00 expecting BNTC to rise to within 12 months (a possible 102.14% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Benitec Biopharma (NASDAQ:BNTC) was provided by Guggenheim, and Benitec Biopharma initiated their buy rating.

There is no last upgrade for Benitec Biopharma

There is no last downgrade for Benitec Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Benitec Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Benitec Biopharma was filed on September 12, 2024 so you should expect the next rating to be made available sometime around September 12, 2025.

While ratings are subjective and will change, the latest Benitec Biopharma (BNTC) rating was a initiated with a price target of $0.00 to $17.00. The current price Benitec Biopharma (BNTC) is trading at is $8.41, which is within the analyst’s predicted range.